ZIVO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ZIVO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Zivo Bioscience's Enterprise Value is $74.23 Mil. Zivo Bioscience's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was $-4.12 Mil. Therefore, Zivo Bioscience's EV-to-FCF for today is -18.00.
The historical rank and industry rank for Zivo Bioscience's EV-to-FCF or its related term are showing as below:
During the past 13 years, the highest EV-to-FCF of Zivo Bioscience was -0.20. The lowest was -30.15. And the median was -8.86.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2025-03-02), Zivo Bioscience's stock price is $19.80. Zivo Bioscience's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-4.880. Therefore, Zivo Bioscience's PE Ratio (TTM) for today is At Loss.
The historical data trend for Zivo Bioscience's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zivo Bioscience Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
EV-to-FCF | Get a 7-Day Free Trial |
![]() |
![]() |
-19.00 | -25.94 | -2.70 | -3.12 | -0.51 |
Zivo Bioscience Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
EV-to-FCF | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
-2.08 | -0.51 | -4.14 | -5.28 | -13.97 |
For the Biotechnology subindustry, Zivo Bioscience's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Zivo Bioscience's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Zivo Bioscience's EV-to-FCF falls into.
Zivo Bioscience's EV-to-FCF for today is calculated as:
EV-to-FCF | = | Enterprise Value (Today) | / | Free Cash Flow (TTM) |
= | 74.231 | / | -4.124 | |
= | -18.00 |
Zivo Bioscience's current Enterprise Value is $74.23 Mil.
Zivo Bioscience's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.12 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zivo Bioscience (OTCPK:ZIVO) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Zivo Bioscience's PE Ratio (TTM) for today is calculated as:
PE Ratio (TTM) | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 19.80 | / | -4.880 | |
= | At Loss |
Zivo Bioscience's share price for today is $19.80.
Zivo Bioscience's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.880.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Thank you for viewing the detailed overview of Zivo Bioscience's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Mark E Strome | 10 percent owner | 100 WILSHIRE BLVD, 15TH FL, SANTA MONICA CA 90401 |
John Bernard Payne | director | 9900 NE 114TH CIRCLE, VANCOUVER WA 98662 |
Alison A Cornell | director | 210 CARNEGIE CENTER, PRINCETON NJ 08540 |
Christopher D. Maggiore | officer: CHIEF FINANCIAL OFFICER | 4788 NOBLES POND DR. NW, CANTON OH 44718 |
Nola E Masterson | director | 768 WEST CALIFORNIA WAY, WOODSIDE CA 94062 |
Strome Mezzanine Fund, Lp | 10 percent owner | 100 WILSHIRE BLVD., SUITE 1750, SANTA MONICA CA 90401 |
Keith Marchiando | officer: Chief Financial Officer | C/O ZIVO BIOSCIENCE, INC., 21 E. LONG LAKE ROAD, SUITE 100, BLOOMFIELD HILLS MI 48304 |
Strome Alpha Fund L P | 10 percent owner | 100 WILSHIRE BLVD SUITE 1750, SANTA MONICA CA 90401 |
Strome Investment Management Lp | 10 percent owner | 100 WILSHIRE BLVD, 15TH FLOOR, SANTA MONICA CA 90401 |
Strome Group, Inc. | 10 percent owner | 100 WILSHIRE BLVD., SUITE 1750, SANTA MONICA CA 90401 |
Hep Investments Llc | 10 percent owner | 2804 ORCHARD LAKE RD, STE 205, KEEGO HARBOR MI 48320 |
Rondeau Robert O Jr | director | 70 WEST LONG LAKE RD, STE 119, TROY MI 48098 |
Thomas Kevin Cox | director | 470 MICHGAMME LANE, LAKE FOREST IL 60045 |
Andrew A Dahl | officer: President, CEO | 7 WEST SQUARE LAKE ROAD, STE 6165, BLOOMFIELD HILLS MI 48302 |
Brian W Young | other: See remarks below. | 1800 NW CORPORATE BLVD, BOCA RATON FL 33431 |
From GuruFocus
By Marketwired Marketwired • 08-11-2021
By Business Wire • 09-19-2023
By Business Wire Business Wire • 04-25-2022
By Business Wire • 07-26-2023
By GlobeNewswire GlobeNewswire • 05-28-2021
By Business Wire Business Wire • 02-10-2023
By Marketwired Marketwired • 06-02-2021
By Business Wire • 10-26-2023
By Business Wire Business Wire • 10-24-2022
By Business Wire Business Wire • 08-10-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.